Audit: QRS - Sh-Polypeptide-9 for Hair Regrowth
Audit conducted on 28/06/2026 01:21 using AI4L / Opus 4.8
Summary
| Items | Count |
|---|---|
| Total | 91 |
| Passed | 91 |
| Failed | 0 |
| N/A | 0 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | All QRS content traces to the ER (Protocol, Benefits, Risks, Interactions, Monitoring, Conclusion). |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | QRS preserves “Theoretical concern”, “promising but unproven”, “uncertain long-term” framing. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Pregnancy/lactation and psoriasis kept as STOP contraindications, not softened. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Categories map faithfully ER→QRS; no cross-category relabeling. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | QRS carries no PMIDs, citations, expert names, NCTs, or brand names. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions introduced. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Matches the ER’s measured, evidence-aware tone. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Maintained throughout. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Presents information without prescribing. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No advisory language. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | Information-presenting voice. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person address. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Plain language used; technical terms glossed or avoided. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Compact card/cell format. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | No direct address. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Framing fits this audience. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Consistent with framing. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Not general-population framed. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | Weighting reflects proactive audience. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging”. Proper names that contain “anti-aging” are quoted verbatim. | 🟢 | No “anti-aging” phrasing present. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language. Direct quotes from sources are exempt. | 🟢 | “injection”, “serum”, “scalp”; no colloquialisms. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card/section headings (“Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”); Gate headings (“Contraindications”, “Key Interactions”); Tier labels (“High”, “Medium”, “Low”, “Speculative”); Monitoring column headers (“Marker”, “Target”, “Why”). | 🟢 | All fixed headings/labels present and unmodified. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All template var spans present. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | Untouched spans unchanged. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. | 🟢 | No empty sections required empty-state phrasing; absent tiers hidden via display:none per 12.5/13.5. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Labels taken verbatim from ER headings. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Labels faithful to ER. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). | 🟢 | No emoji indicators (grep confirmed). |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Content condensed to one-page budget. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Comment is first element (lines 2–14). |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. | 🟢 | ”—” delimiters at lines 3 and 13. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Inside HTML comment; not rendered. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Values trimmed; only “duration” quoted (contains colon). |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | er_filename: sh_polypeptide_9_hair_2026-0628-0004_Opus_ER.md |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | qrs_prompt_version: 26.5.18 |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” | 🟢 | qrs_creation_date: 2026-0628-0004 |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | qrs_creator_ai_nickname: Opus |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. | 🟢 | “Opus” — single word. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | qrs_creator_ai_fullname: Opus 4.8 |
| 5.11 | The full name of the AI consists of the nickname and the model version number and no additional qualifier. | 🟢 | “Opus 4.8” — nickname + version. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | qrs_filename: sh_polypeptide_9_hair_2026-0628-0004_Opus_QRS.html |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value requires YAML quoting. | 🟢 | Consistent and clean. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet”. The [canonical_topic] is HTML-entity-encoded as needed. | 🟢 | “Sh-Polypeptide-9 for Hair Regrowth - Quick Reference Sheet”; no entities required. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed. | 🟢 | “Sh-Polypeptide-9 for Hair Regrowth”. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | 2026-0628 → 06/28/2026. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | “Opus 4.8”. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header carries only the permitted fields. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Condenses the ER Conclusion faithfully. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 48 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each clause traces to the Conclusion (biology sound, blends, seller conflict, unproven add-on). |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | “blood-vessel-growth signal”, “add-on” — plain language. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial citations. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No statistics. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Derived from “Populations who should avoid it” / “Population thresholds”. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | Psoriasis, scalp cancer, sunburn/UV, pregnancy/lactation, systemic anti-VEGF therapy. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Each item is its own <li>. |
| 8.4 | Items are as concise as possible. No trailing explanations, elaborations, rationale, attributions, citations, study details, or content after a dash. | 🟢 | Concise; no trailing clauses. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept concise. | 🟢 | “active scalp plaques”, “recent high-UV exposure” retained. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>”) that depends on an explanatory phrase, normalize to a plain comma-separated list. | 🟢 | No ranking notation present; items already plain. |
| 8.7 | If no [stop_items] are present the section is left empty | 🟢 | Stop items are present; section populated. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Derived from OTC/additive interaction bullets. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any already listed as Contraindications | 🟢 | Anti-VEGF therapy excluded (it is a contraindication); irritants/acids and angiogenic actives retained. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Each item is its own <li>. |
| 9.4 | Items are as concise as possible. No trailing explanations, rationale, attributions, citations, study details, or content after a dash. | 🟢 | Concise; no trailing clauses. |
| 9.5 | Parenthetical qualifiers — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved, kept concise. | 🟢 | “(copper peptides / GHK-Cu, procyanidins, topical minoxidil)” preserved. |
| 9.6 | When the ER uses ranking notation inside parens that depends on an explanatory phrase, normalize to a plain comma-separated list. | 🟢 | No ranking notation present; list already plain. |
| 9.7 | If no [caution_items] are present the section is left empty | 🟢 | Caution items present; section populated. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | Derived from Therapeutic Protocol bullets. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Topical serum, intradermal injection, dosing pattern. |
| 10.3 | If less than three distinct actionable implementation aspects are mentioned, unused sets are left empty and made invisible. | 🟢 | Three aspects available; all sets used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All cells populated from ER (once/twice daily; every 2–3 weeks; repeated low-dose). |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Earliest effect, blend-study assessment, full reassessment. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Ordered earliest → assessment → reassessment, consistent with ER emphasis. |
| 11.3 | If less than three distinct time-to-effect aspects are mentioned, unused sets are left empty and made invisible. | 🟢 | Three aspects available; all sets used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | 3–6 months, 3–4 months, 6 months+ — all ER-sourced. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
🟢 | ER provides time-to-effect data; section retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | Derived from Medium/Low/Speculative benefit tiers. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four variables present. |
| 12.3 | Items are as concise as possible. No explanations, elaborations, effect sizes, qualifiers, attributions, citations, study details, or mechanistic explanations. | 🟢 | Concise key facts only. |
| 12.4 | Parenthetical content — effect sizes, sample notes, mechanistic hints, example studies — is stripped, NOT preserved. | 🟢 | “(Anagen Support)” stripped from medium benefit. |
| 12.5 | If no items of a specific sub-section are present the respective is set to “display=none”, not filled with empty-state phrasing. | 🟢 | benefits_high set to display:none (ER has no High tier). |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | Derived from Low/Speculative risk tiers. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four variables present. |
| 13.3 | Items are as concise as possible. No explanations, elaborations, effect sizes, qualifiers, attributions, citations, study details, or mechanistic explanations. | 🟢 | Concise key facts only. |
| 13.4 | Parenthetical content — frequencies, severity grades, sample notes, mechanistic hints, example studies — is stripped, NOT preserved. | 🟢 | No parentheticals carried into risk items. |
| 13.5 | If no items of a specific sub-section are present the respective is set to “display=none”, not filled with empty-state phrasing. | 🟢 | risks_high and risks_medium set to display:none (ER has no High/Medium tiers). |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Derived from the ER Monitoring Protocol table. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | Ferritin, TSH, Vitamin D (25-OH), Zinc — all four listed. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Baseline, ~3 months, 6 months, then every 6 months. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Derived from the ER qualitative-markers list. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All four qualitative markers (shedding, regrowth, pull test, density) listed. |
Issues 28/06/2026 01:21
Pass rate 100.00%. No issues found.
Issues 28/06/2026 01:17
- 12.4 — Parenthetical not stripped: benefits_medium (line 525) retains the parenthetical “(anagen support)”; item 12.4 requires parenthetical content to be stripped, not preserved.
Fixes 28/06/2026 01:17
- 12.4 — Parenthetical not stripped: Removed the parenthetical “(anagen support)” from benefits_medium, changing “Increased perifollicular blood supply (anagen support)” to “Increased perifollicular blood supply”.